Abstract
Incretins including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase Ⅳ (DPP-4) inhibitors are a new type of anti-hyperglycemic drugs. Generally speaking, GLP-1 analogues are associated with significant weight loss, and DPP-4 inhibitors have a neutral effect on body weight. However, they still cause weight gain, particularly when combined with sulfonylureas or thiazolidinedione. Clinicians should be aware of the influence on body weight of GLP-1 analogues and DPP-4 inhibitors, which can lay the foundation for developing more rational, safe and effective treatments for patients with type 2 diabetes. Key words: Type 2 diabetes mellitus; Glucagon-like peptide 1 receptor agonists; Dipepidyl peptidase 4 inhibitors; Body weight
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
